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Abstract
Background: To reduce global tuberculosis (TB) burden, the active disease must be diagnosed quickly and
accurately and patients should be treated and cured. In Ethiopia, TB diagnosis mainly relies on spot-morning-spot
(SMS) sputum sample smear analysis using Ziehl-Neelsen staining techniques (ZN). Since 2014 targeted use of xpert
has been implemented. New diagnostic techniques have higher sensitivity and are likely to detect more cases if
routinely implemented. The objective of our study was to project the effects of alternative diagnostic algorithms on
the patient, health system, and costs, and identify cost-effective algorithms that increase TB case detection in Addis
Ababa, Ethiopia.
Methods: An observational quantitative modeling framework was applied using the Virtual Implementation
approach. The model was designed to represent the operational and epidemiological context of Addis Ababa, the
capital city of Ethiopia. We compared eight diagnostic algorithm with ZN microscopy, light emitting diode (LED)
fluorescence microscopy and Xpert MTB/RIF. Interventions with an annualized cost per averted disability adjusted life
year (DALY) of less than the Gross Domestic Product (GDP) per capita are considered cost-effective interventions.
Results: With a cost lower than the average per-capita GDP (US$690 for Ethiopia) for each averted disability
adjusted life year (DALY), three of the modeled algorithms are cost-effective. Implementing them would have
important patient, health system, and population-level effects in the context of Addis Ababa
❖ The full roll-out of Xpert MTB/RIF as the primary test for all presumptive TB cases would avert 91170 DALYs (95%
credible interval [CrI] 54888 – 127448) with an additional health system cost of US$ 11.6 million over the next 10
years. The incremental cost-effectiveness ratio (ICER) is $370 per DALY averted.
❖ Same day LED fluorescence microscopy for all presumptive TB cases combined with Xpert MTB/RIF targeted to
HIV-positive and High multidrug resistant (MDR) risk groups would avert 73600 DALYs( 95% CrI 48373 - 99214) with
an additional cost of US$5.1 million over the next 10 years. The ICER is $169per DALY averted.
❖ Same-day LED fluorescence microscopy for all presumptive TB cases (and no Xpert MTB/RIF) would avert 43580
DALYs with a reduction cost of US$ 0.2 million over the next 10years. The ICER is $13 per DALY averted.
Conclusions: The full roll-out of Xpert MTB/RIF is predicted to be the best option to substantially reduce the TB
burden in Addis Ababa and is considered cost effective. However, the investment cost to implement this is far beyond
the budget of the national TB control program. Targeted use of Xpert MTB/RIF for HIV positive and high MDR risk
groups with same-day LED fluorescence microscopy for all other presumptive TB cases is an affordable alternative.
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Background
According to the WHO global tuberculosis (TB) report
[1], Ethiopia is one of the 30 high TB burden countries
with an estimated prevalence of TB of 200 (161–243)
per 100, 000 population. Despite all the efforts and
commitments exerted and opportunities availed, the
Ethiopian national tuberculosis program (NTP) is still
facing many challenges which possibly compromise the
coverage and quality of TB prevention and control activ-
ities: one of the challenges is low TB case detection rate.
A major hurdle contributing to the low TB case detec-
tion rate is the lack of an accurate diagnostic algorithm.
In Ethiopia screening strategies for presumptive tubercu-
losis cases mainly depends on a combination of symp-
tom screening and microscopy using 3 samples (spot-
morning-spot) and for some cases chest X-ray [2]. This
is a major shortcoming as it is now well established that
these standard diagnostic tools perform sub-optimally
[3]. In one study conducted in Addis Ababa’s health fa-
cilities, the sensitivity of Ziehl-Neelsen(ZN) microscopy
was found to be 29.2% [4]. Other, studies have demon-
strated that the diagnostic delay of smear microscopy re-
sulted in a significant loss-to-follow-up of active TB
patients after initial screening [3, 5]. Screening strategies
based on culture are more accurate, but are often very
expensive, not routinely available and take several weeks
to come to diagnosis [2], which compromises patient
follow-up and traceability.
Ethiopia is implementing targeted use of Xpert MTB/
RIF since 2014 [6], and the utilization is suboptimal.
New diagnostic tools for TB have the potential to deliver
substantial reductions in the burden of disease through
improved sensitivity [7], lower diagnostic default, less
delay to starting appropriate treatment and reductions in
TB incidence [5]. Thus, the need for full implementation
of newer diagnostic approaches for case detection in
Ethiopian context is urgent. However, these new tools
are more costly than the conventional diagnostic tools.
Accordingly, policymakers must decide on the best com-
bination of tools to choose; who should be tested with
the new tools; whether the new tools complement or
replace the existing diagnostics; and on the general im-
pact of implementing the new tools on patients, health
systems and epidemiological burden [8–10]. It would be
expensive, time-consuming and disruptive to the health
system to try and answer all these questions through ex-
perimentation in the live environment. Mathematical
modeling has the potential of addressing the above
questions to help guide policy makers in the most op-
timal and cost-effective use of new diagnostic tools
[11, 12]. Modeling can project the effect of rolling out
the new algorithm on the number of patients diagnosed,
treated and cured. This enables each new diagnostic
option to be evaluated and compared in terms of the
number of disability adjusted life years (DALY’s) averted,
incremental cost-effectiveness ratio’s (ICER), and sustain-
ability. Different combinations or packages of tests and
approaches can be modeled. This study is proposed to
assess the impact of alternative diagnostic algorithms on
tuberculosis detection using a modeling approach in a
district of Addis Ababa, Ethiopia. The analysis adds to
other work on this topic [5, 9, 12–14].
Methods
Study setting and algorithms
The study was conducted for public health facilities
which provide the Directly Observed Treatment (DOT)
services to TB patients in Addis Ababa , Ethiopia. We
compared the impact of eight diagnostic algorithms.
These were chosen based on WHO [15] and Ethiopian
ministry of Health [6] recommendations. Routine diag-
nostic algorithms, that are common in the country, were
also considered. Under the ZN-Spot-Morning-Spot
scenario, Ziehl-Neelsen (ZN) microscopy using three
sputum samples provided within two days was modeled.
This scenario represents the common diagnostic algo-
rithms for presumptive TB patients when there is no
access to Xpert MTB/RIF (expert opinion). In this
model, it was considered as the base case for comparison.
FN-Spot-Morning-Spot scenario replaces ZN micros-
copy with light-emitting diode (LED) fluorescence micros-
copy. FN-Spot-Morning and FN-Spot-Spot scenarios
use LED Fluorescence microscopy using two sputum
samples provided within two days (on the SPOT-early
MORNING) and on the same day (on the SPOT-SPOT),
respectively. Full-Xpert scenario tests all patients with
presumptive tuberculosis with Xpert. Targeted-Xpert-
MDR-HIV-ZN-Spot-Morning-Spot scenario uses ZN
microscopy (SPOT-MORNING-SPOT) as the primary
test for tuberculosis diagnosis and target Xpert for
presumptive TB cases that are HIV positive, known
contact of MDR-TB patients, and retreatment cases. But
Targeted-Xpert-ZN-Negative-Spot-Morning-Spot sce-
nario targets the use of Xpert to a patient with presump-
tive TB who are smear negative in addition to a patient
who is HIV positive, known contact of MDR-TB patients,
and retreatment case. Targeted-Xpert-MDR-HIV-FN-
Spot-Spot scenario uses LED fluorescence microscopy on
the same day (SPOT-SPOT) as the primary test for tuber-
culosis diagnosis and target Xpert for presumptive TB
cases who are HIV positive, known contact of MDR-TB
patients, and retreatment cases. Figure 1 Illustrate the
diagnostic algorithms used in the analysis.
Model structure
We adopted a modeling framework pioneered by Langley
et al. in Tanzania [5] to represent the operational and
epidemiological context of Addis Ababa, Ethiopia. The
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model used the discrete-event simulation (DES) approach
and Witness software to represent the patient pathways
that individual patients follow and the sputum sample
pathways in the laboratory.
The patient pathways, the patient was categorized as
either new cases or retreatment cases, and HIV+ or
HIV- with some knowing their status and some not.
Multiple visits to the diagnostic center are required by
each new patient. The number of visits for each patient
is dependent on a number of factors which were mod-
eled. These factors included the diagnostic test; whether
the patient became diagnostic lost to follow-up (LTFU);
the backlog in the laboratory that could lead to diagnosis
not being available; the time the patient was willing to
wait in the diagnostic centre for results; whether the ini-
tial test result was positive; whether X-ray and a short
course of antibiotics was required following a negative
sputum test; and whether TB treatment would be
required. Once TB has been diagnosed a further visit to
the diagnostic center is required to receive the first
batch of medication and for treatment education. Pa-
tients return to the diagnostic center during treatment
for sputum smear microscopy testing at the end of each
phase of treatment. Patients are finally categorized as
cured, completed, failed treatment, or treatment lost to
follow-up.
In sputum sample pathways, sputum samples are
collected in the diagnostic center from presumptive TB
cases and individuals undergoing treatment for TB. Sam-
ples follow a pathway through the laboratory depending
on the patient characteristics, diagnostic technique, and
the diagnostic algorithm being used. There were two
different types of diagnostic test that were modeled –
microscopy and Xpert. These were modeled separately
with control logic defining which test process would be
used for which patient sample based on the ‘attributes’
Fig. 1 Patient pathway for diagnostic algorithms. a Sputum microscopy. b Xpert MTB/RIF. c Xpert MTB/RIF in addition to microscopy
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of the patient. This logic enabled a number of different
diagnostic algorithms to be evaluated. Samples are pre-
pared for the appropriate test, the test is then conducted
and a test result assigned.
For simplicity, we assumed a constant population with
no immigration or emigration and constant transmission
dynamics. Further details on the model and parameter
descriptions are given in the Additional file 1 and other
references [5, 11]. The model was calibrated by using
real data from diagnostic centers in Addis Ababa. The
outputs from the model were validated against the
observed results from diagnostic centers.
Considering the natural history and pathogenesis of
tuberculosis that take generations for the effects of inter-
vention to be seen and situational changes due to new
diagnostics technologist in pipeline, we choose a time-
frame of 10 years for prediction.
Diagnostic and cost parameters
A survey of one central referral laboratory and 20 public
health facilities that provide TB services provided
(randomly selected) estimates for the diagnostic and cost
parameters to be used in the model (Additional file 1:
Table B). Sensitivity and specificity of diagnostic tools
were collated from the literature [16–18] (Additional
file 1: Table A). Data were collected from August to
December 2014. Additional file 1: part A and B lists the
model variables and their sources.
Cost variables and source of the data are presented in
Additional file 1: part C. Unit costs were input in US
dollars and are based on published data and estimates
from Ethiopian National Tuberculosis program, Addis
Ababa Health Bureau, and Health facilities. We used
public sector salary scale of 2014 to estimate annual em-
ployment cost using National Bank of Ethiopia exchange
rate (19.7 Birr= 1 USD). Consolidated Health Economic
Evaluation Reporting Standards (CHEERS) [19] was used
for reporting of economic evaluation results.
Uncertainty analysis
We conducted uncertainty analysis to estimate the 95%
credible interval of projected outcome, accounting for
the uncertainty of input parameter values. In the oper-
ational component, each simulated year involved run-
ning the model for over 2,500 simulated days. Outcomes
were recorded for each simulated 90 day period and the
mean and standard deviation calculated. From these,
95% confidence limits for key outcome measures were
calculated.
Cost-effectiveness analysis
Cost-effectiveness measures were calculated to compare
different diagnostic options. The incremental cost of
implementing each alternative diagnostic option was
derived from the Addis Ababa health system perspective,
and included the additional annual running costs (eg,
consumables, susceptible and drug resistant -tubercu-
losis drugs, radiographs, equipment maintenance, and
laboratory personnel) and the investment costs (eg,
microscopes and the equipment related to Xpert imple-
mentation) (Additional file 1). Other overhead costs
were assumed to be unaffected by a change in the diag-
nostic algorithm. The introduction of new tuberculosis
diagnostics is expected to improve the survival of pa-
tients co-infected with tuberculosis and HIV, therefore
we estimated the incremental costs from additional anti-
retroviral therapy (ART) on the basis of the projected
increase in HIV prevalence resulting from reductions in
the number of deaths from tuberculosis with HIV co-
infection. The population effect on tuberculosis epidemi-
ology was summarized using disability- adjusted life
years (DALYs). Costs and DALYs were calculated over
10 years with an annual discount rate of 3%. We calcu-
lated the average cost-effectiveness ratio (ACER) by
comparing each alternative diagnostic option to the base
case scenario. Because the alternative diagnostic options
are mutually exclusive interventions that compete for
the same resources, we also calculated the incremental
cost- effectiveness ratios (ICER) to compare one option
with the next less-effective option. The estimated ICER
was compared with the willingness-to-pay threshold for
Ethiopia (US$690 based on the gross domestic product
[GDP] per capita in 2015) [20]. Interventions with an
ICER of less than the Gross Domestic Product (GDP)
per capita considered as cost-effective interventions [21]
but need to be considered alongside affordability, budget
impact, fairness, feasibility and any other criteria consi-
dred important in the local.
Results
Patient-level Impact
The full roll-out of Xpert MTB/RIF is projected to pro-
duce the greatest patient-level benefits among the eight
alternative diagnostic options (Table 1). The modeling
result showed that mean patient visits for diagnosis re-
duces by an average of 1·4 visits, time to start treatment
reduces by an average of 7.8 days, and the diagnostic lost
to follow-up rate reduces by 9% compared to the base
case (ZN-Spot-Morning-Spot). The likelihood that a
patient with tuberculosis will successfully complete
diagnosis and treatment is increased by 8.3%. The next
best algorithms from the patient perspective involve tar-
geting of Xpert MTB/RIF to HIV-positive cases and high
MDR risk groups alongside same day LED for the other
TB presumptive cases (Targeted-Xpert-MDR-HIV-
FN-Spot-Spot) and Xpert as a secondary test for
smear negative new TB suspects (Targeted-Xpert-
ZN-Negative-Spot-Morning-Spot).
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Health system Impact
Under full scale-up of Xpert, the required number of
sputum samples per year is 54,000 compared to 113,000
under the base case. The full roll-out of Xpert requires
only 33.3% of the laboratory staff time that is needed for
the base case (Table 2). There is no significant change in
drug sensitive tuberculosis notification among the alter-
native diagnosis algorithms. After false-positive cases are
excluded, full Xpert scale-up is projected to increase the
number of true tuberculosis cures by 346 (Table 2). The
use of Xpert would also identify 207 rifampicin-resistant
cases during the diagnostic process compared with only
59 MDR tuberculosis cases under the base case. Xpert
reduces missed TB cases (patients with TB but not diag-
nosed or lost to follow-up) by 341 patients compared
with the base case.
Cost-effectiveness analysis
The modeling analysis indicated that full roll-out of
Xpert is expected to avert approximately 9117 DALYs
per years at average cost-effectiveness ratio (ACER) of
$127 per disabilityadjusted life year (DALY) averted
compared to the base case (Table 3). The average cost-
effectiveness ratio (ACER) of other alternative diagnostic
options ranged from $2 to $203 per DALY averted com-
pared with the base case. Xpert as the primary test for
HIV-positive cases and high MDR risk group alongside
LED same day for all others (Targeted-Xpert-MDR-
HIV-FN-Spot-Spot) is expected to avert 7360 DALYs
per year and Xpert as secondary tests for smear negative
new presumptive TB cases (Targeted-Xpert-ZN-Nega-
tive-Spot-Morning-Spot) is expected to avert 4724
DALYs. Other diagnostic algorithms would have less
Table 1 Patient-level effects of new diagnostic algorithms
Diagnostic algorithms Diagnosis and treatment initiation Diagnosis and treatment success
Number of visits to
the diagnostic center
Time to start
treatment (Days)
Diagnostic
LTFUa rate (%)
New tuberculosis cases
diagnosed without a
positive sputum test (%)
Likelihood of a true
tuberculosis patient
completing diagnosis
and treatment (%)
ZN-Spot-Morning-Spot 5 16.8 13.3 59.8 76.6
FN-Spot-Morning-Spot 4.9 15 12.6 52.9 78.4
Targeted-Xpert-ZN-Negative-
Spot-Morning-Spot
4.4 10.5 11.8 28.6 80.9
Targeted-Xpert- MDR-HIV-ZN-Spot-
Morning-Spot
4.7 15.2 12.1 52.5 79.2
Full-Xpert 3.6 9 4.3 28.9 84.9
FN-Spot-Spot 4.4 16 8.6 56.6 80.6
FN-Spot-Morning 4.9 15.5 13.1 52.4 78.2
Targeted-Xpert-MDR-HIV-FN-Spot-Spot 4.1 14.6 6.8 49.4 83.3
aLTFU-Lost to follow up
Table 2 Health-system-level effects of new diagnostic algorithms: mean per year in 10 years
Diagnostic algorithms Sputum samples tested
for tuberculosis per year
Lab staff
utilization (%)
Patients starting tuberculosis
treatment per year including
false positive
Missed TBa
per year
Complete cures
per year excluding
false positive
Microscopy
(000s)
Xpert
(000s)
X-ray
(000s)
Standard
regimen
Treatment
complete/cure
Treatment
failure/MDR TB
ZN-Spot-Morning-Spot 113 0 12 30 6200 5919 59 963 3154
FN-Spot-Morning-Spot 112 0 12 22 5874 5608 59 893 3228
Targeted-Xpert-ZN-Negative-
Spot-Morning-Spot
93 33 6 30 5257 4927 148 785 3332
Targeted-Xpert- MDR-HIV-
ZN-Spot-Morning-Spot
98 7 11 28 6165 5831 118 859 3263
Full-Xpert 17 37 6 10 5588 5189 207 622 3500
FN-Spot-Spot 86 0 12 17 6269 5984 59 800 3322
FN-Spot-Morning 82 0 12 16 6200 5919 59 963 3154
Targeted-Xpert-MDR-HIV-
FN-Spot-Spot
76 7 12 1 5874 5608 59 893 3228
aMissed TB- Patient with TB but not diagnosed or lost to follow up
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effect on DALYs, with the benefits ranging from 1747
(FN-Spot-Morning) to 4358 (FN-Spot-Spot) DALYs
averted per year. The full rollout of Xpert requires an
additional budget of an average US$ 1,161,133 budget
per year over 10 years. Incremental cost for the other al-
ternative algorithms varies between –US$ 52,727 and
US$950,669 over the next 10 years (Table 3, Fig. 2).
In the analysis of the incremental cost-effectiveness ratio
(ICER) options FN-Spot-Morning-Spot, Targeted-
Xpert-ZN-Negative-Spot-Morning-Spot, and Targeted-
Xpert-MDR-HIV-ZN-Spot-Morning-Spot are strongly
dominated by same-day LED fluorescence microscopy
(FN-Spot-Spot), LED same day with Xpert (Targeted-
Xpert-MDR-HIV-FN-Spot-Spot) , and Xpert full rollout;
because they produce DALY gains at a higher incremental
cost . The ICER of Xpert full rollout is $370.1 per DALY
averted , followed by LED Same Day + Xpert for HIV
positive and high MDR risk group (Targeted-Xpert-
MDR-HIV-FN-Spot-Spot) ($176.7), same-day LED fluor-
escence microscopy ($12.6) and LED fluorescence micros-
copy with two sample (-$30.2) (Table 3). The ICERs for
the above alternative algorithms are lower than the annual
per-capita GDP of Ethiopia (US$690) [20] and are deemed
cost-effective.
Discussion
In this study, we used a modeling approach to evaluate
the potential patient and health system effects and to
complete a cost effective analysis of eight diagnostic
algorithms. Our results indicated that full roll-out of
Xpert in Addis Ababa city would have the greatest
patient-level and health system benefits, and would be
cost effective with the highest DALYs averted among the
alternative diagnostic options. The improved diagnostic
Table 3 Cost-effectiveness analysis of new diagnostic algorithms
Diagnostic algorithms DALYs averted per year Additional health system
costs per year over 10
years (US$)
Cost-effectiveness ratio
(US$ per DALY averted)
YLL YLD DALY ACER ICER
ZN-Spot-Morning-Spot 0 0 0
FN-Spot-Morning-Spot 1935 25 1965 3456 2 Dominated
Targeted-Xpert-ZN-Negative-Spot-Morning-Spot 4660 64 4724 950669 201 Dominated
Targeted-Xpert- MDR-HIV-ZN-Spot-Morning-Spot 2838 39 2878 582813 203 Dominated
Full-Xpert 8988 128 9117 1161133 127 370.1
FN-Spot-Spot 4299 59 4358 -19748 -5 12.6
FN-Spot-Morning 1728 25 1747 -52727 -30 -30.2
Targeted-Xpert-MDR-HIV-FN-Spot-Spot 7256 104 7360 510831 69 176.7
YLL years of life lost, YLD years lost due to disability, DALY disability adjusted life year. ACER average cost-effectiveness ratio, ICER incremental cost-effectiveness ratio
G
C B
D
F
E
A
Fig. 2 Additional health system budget versus average cost-effectiveness ratio (ACER) versus disability-adjusted life-years (DALYs) averted
of alternative diagnostic algorithms. A= FN-Spot-Morning-Spot scenario, B= Targeted-Xpert-ZN-Negative-Spot-Morning-Spot scenario,
C= Targeted-Xpert- MDR-HIV-ZN-Spot-Morning-Spot scenario, D= Full-Xpert scenario, E= FN-Spot-Spot scenario, F= FN-Spot-Morning
scenario, and G= Targeted-Xpert-MDR-HIV-FN-Spot-Spot
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sensitivity and the need for only one sputum sample for
Xpert reduce mean patient visits for diagnosis, time to
start treatment, and diagnostic lost to follow-up rate.
This result in an increase in the likelihood that a patient
with TB will successfully complete diagnosis and treat-
ment. It would result in an additional health system cost,
and an incremental cost to the HIV program due to
longer life expectancy for co-infected TB and HIV pa-
tients. We note that cost-effectiveness does not neces-
sarily mean that the implementation is affordable for the
Addis Ababa tuberculosis control program.
A more affordable cost effective alternative is targeted
use of Xpert MTB/RIF for HIV positive and high MDR
risk groups with same-day LED fluorescence microscopy
for all other presumptive tuberculosis cases (Targeted-
Xpert-MDR-HIV-FN-Spot-Spot). The result is in line
with the current effort of national tuberculosis program
to scale-up LED fluorescent microscopy and targeted
use of Xpert. The third cost effective alternative is same
day LED fluorescence microscopy (FN-Spot-Spot). The
improved diagnostic sensitivity of LED microscopy, and
the need for sputum with in the same day reduce diag-
nostic lost-to follow up rate. This result in better per-
formance of this option as compared to ZN microscopy
with spot-morning, and FN spot-morning. The weak
part of this option is do not have a room for drug resist-
ant TB.
The other options are not cost effective, with DALY
gains at a higher incremental cost and additional health
system costs while they are less effective than the above
three for the context of Addis Ababa, Ethiopia. The
World Health Organization has endorsed the use of
same day LED fluorescent microscopy in 2011 [16].
However, in Ethiopia it has not been implemented. Our
result also shows that a diagnosis based on 3 (SMS)
samples is not cost effective compared to Spot-spot LED
fluorescence microscopy. It requires additional patient
visits for diagnosis, sputum, and laboratory staff time. It
results in higher diagnostic lost to follow-up rate, higher
patient and health system costs, and a decrease in the
likelihood that a patient with tuberculosis will success-
fully complete diagnosis and treatment. The national
technical working group should discuss this issue for
giving advice to policy makers on the most optimal and
cost-effective diagnostic algorithm.
Our results are in line with the findings of Langley et al.
in Tanzania [1] where projections due to full Xpert rollout
meant patient visits for diagnosis reduced by 1.2 (95% CrI
1.1 – 1.3)visits, time to start treatment by 6·6 (95% CrI
5·9–7·3) days, and the diagnostic lost to follow-up rate by
7% (95% CrI 6–9), the likelihood that a patient with tuber-
culosis will successfully complete diagnosis and treatment
increased by 18%. They also reported highest DALY
averted, and a reduction of the number of sputum samples
by 34%, and laboratory staff time by 45%. In both studies,
the effect of the alternative algorithms on tuberculosis
case notification was the same and marginal. The reason
behind this is that the increase in case detection is coun-
terbalanced by a reduction in the number of false
positives. Our results are also in line with other studies
([22, 23]) where novel diagnostics can substantially reduce
TB transmission.
We found a scenario whereby targeted use of Xpert
is cost effective (Targeted-Xpert-MDR-HIV-FN-Spot-
Spot). This is cost effective because besides the targeted
use we introduce same day LED fluorescence microscopy
to those not benefitting from Xpert. The other
algorithms with targeted use of Xpert (Targeted-Xpert-
ZN-Negative-Spot-Morning-Spot & Targeted-Xpert-
MDR-HIV-ZN-Spot-Morning-Spot) are not cost effect-
ive compared to all other options. The reason for the
inferior cost-effectiveness is that the projected costs are
substantially higher while the projected gains in DALYs
are lower than same day LED fluorescence microscopy in
combination with Xpert. Similarly, in the Tanzania
study targeting of Xpert either to HIV positive or smear
negative HIV-positive cases was not cost-effective [5].
A number of limitations were observed in our mod-
eling analysis. All epidemiological modeling results
are uncertain [22]. It is affected by uncertainty of var-
iables and assumptions on model structures. Uncer-
tainty analyses were done only for few parameters.
Data accuracy can be a constraint with modeling. Full
health system costing was not considered. Users of
the modeling result should take account that a mod-
eling analysis cannot consider all the practical chal-
lenges that might arise from implementation of a new
diagnostic methods.
Conclusions
In conclusion, we suggest that Ethiopian TB program to
consider switching to Same-day diagnosis according to
WHO recommendation on using same day LED fluores-
cent microscopy on two spot samples. The full roll-out
of Xpert MTB/RIF was predicted to be the best option
to substantially reduce the TB burden in Addis Ababa
and was considered cost effective. However, the required
resources to implement this are beyond the budget of
the TB control program. Targeted use of Xpert MTB/
RIF for HIV positive and high MDR risk groups with
same-day LED fluorescence microscopy for all other pre-
sumptive TB cases is an affordable alternative. In a
broader perspective, our results also highlight the im-
portance of a modeling approach to support the selec-
tion and implementation of the optimal diagnostic
algorithm and outlined the delicate balance between
maximizing impact but coming up with an affordable
diagnostic algorithm option.
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